Pacific Biosciences of California (STU:P09) Cyclically Adjusted FCF per Share: €-0.66 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:P09 Pacific Biosciences of California Inc STU:P09
60 GF Score
Price €1.30
GF Value €1.41
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Pacific Biosciences of California Cyclically Adjusted FCF per Share?

Pacific Biosciences of California STU:P09 -2.40% 60 Cyclically Adjusted FCF per Share is €-0.66 as of Mar. 2026. GuruFocus rates STU:P09 with a GF Score™ of 60/100 and a GF Value™ of €1.41 (Fairly Valued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pacific Biosciences of California's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.149. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.66 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -1.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 1.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pacific Biosciences of California was 63.30% per year. The lowest was -2.20% per year. And the median was 1.05% per year.

As of today (2026-07-17), Pacific Biosciences of California's current stock price is €1.2995. Pacific Biosciences of California's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.66. Pacific Biosciences of California's Cyclically Adjusted Price-to-FCF of today is .


Pacific Biosciences of California  (STU:P09) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pacific Biosciences of California Cyclically Adjusted FCF per Share Related Terms


Pacific Biosciences of California Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Pacific Biosciences of California's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacific Biosciences of California Cyclically Adjusted FCF per Share Chart

Pacific Biosciences of California Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.64 -0.66 -0.74 -0.77 -0.59

Pacific Biosciences of California Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -0.67 -0.62 -0.59 -0.66

STU:P09 vs KIDS, MOBI, SI: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Cyclically Adjusted Price-to-FCF falls into.


STU:P09
60GF Score
Pacific Biosciences of California Inc STU:P09
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacific Biosciences of California Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pacific Biosciences of California's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.149/330.2130*330.2130
=-0.149

Current CPI (Mar. 2026) = 330.2130.

Pacific Biosciences of California Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.219 241.018 -0.300
201609 -0.176 241.428 -0.241
201612 -0.159 241.432 -0.217
201703 -0.194 243.801 -0.263
201706 -0.149 244.955 -0.201
201709 -0.153 246.819 -0.205
201712 -0.154 246.524 -0.206
201803 -0.125 249.554 -0.165
201806 -0.103 251.989 -0.135
201809 -0.091 252.439 -0.119
201812 -0.112 251.233 -0.147
201903 -0.155 254.202 -0.201
201906 -0.105 256.143 -0.135
201909 -0.107 256.759 -0.138
201912 -0.108 256.974 -0.139
202003 0.437 258.115 0.559
202006 -0.139 257.797 -0.178
202009 -0.093 260.280 -0.118
202012 -0.052 260.474 -0.066
202103 -0.101 264.877 -0.126
202106 -0.072 271.696 -0.088
202109 -0.165 274.310 -0.199
202112 -0.138 278.802 -0.163
202203 -0.338 287.504 -0.388
202206 -0.272 296.311 -0.303
202209 -0.302 296.808 -0.336
202212 -0.274 296.797 -0.305
202303 -0.380 301.836 -0.416
202306 -0.162 305.109 -0.175
202309 -0.243 307.789 -0.261
202312 -0.204 306.746 -0.220
202403 -0.247 312.332 -0.261
202406 -0.190 314.175 -0.200
202409 -0.147 315.301 -0.154
202412 -0.091 315.605 -0.095
202503 -0.157 319.799 -0.162
202506 -0.086 322.561 -0.088
202509 -0.053 324.800 -0.054
202512 -0.056 324.054 -0.057
202603 -0.149 330.213 -0.149

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.66 mean?
Pacific Biosciences of California (STU:P09) has a Cyclically Adjusted FCF per Share of €-0.66 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pacific Biosciences of California and its competitors.
Is Pacific Biosciences of California's Cyclically Adjusted FCF per Share too high?
Pacific Biosciences of California's current Cyclically Adjusted FCF per Share is €-0.66. Overall, Pacific Biosciences of California has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pacific Biosciences of California's Cyclically Adjusted FCF per Share compare to KIDS and MOBI?
Pacific Biosciences of California's Cyclically Adjusted FCF per Share of €-0.66 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pacific Biosciences of California and its competitors. Pacific Biosciences of California's current Cyclically Adjusted FCF per Share is €-0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Biosciences of California stock overvalued right now?
Based on GuruFocus' analysis, Pacific Biosciences of California (STU:P09) is currently considered Fairly Valued. The stock's GF Value™ is €1.41, compared to a current price of €1.30 — trading 7.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.66. Pacific Biosciences of California's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Pacific Biosciences of California (STU:P09), the current Cyclically Adjusted FCF per Share is €-0.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacific Biosciences of California (STU:P09) Overvalued in 2026?

Based on GuruFocus' analysis, Pacific Biosciences of California stock appears to be undervalued. The current stock price of €1.30 is trading 7.8% below its estimated GF Value™ of €1.41. GuruFocus considers Pacific Biosciences of California to be Fairly Valued.

Key valuation signals for STU:P09:

  • Cyclically Adjusted FCF per Share: €-0.66
  • GF Value™: €1.41 vs. price of €1.30 (7.8% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the STU:P09 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pacific Biosciences of California Business Description

Other Exchanges PACB:USA
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
60GF Score

Get the complete analysis for STU:P09

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.30
Price
€1.41
GF Value